Commonwealth Equity Services, LLC Aurinia Pharmaceuticals Inc. Transaction History

Commonwealth Equity Services, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$4.93 - $9.31 $55,743 - $105,268	11,307 New	11,307 $57,000
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $666 - $1,239	100 Added 0.93%	10,857 $81,000
Q2 2022 Jul 19, 2022	BUY	$8.95 - $12.8 $4,179 - $5,977	467 Added 4.54%	10,757 $108,000
Q1 2022 May 04, 2022	SELL	$10.05 - $22.48 $19,567 - $43,768	-1,947 Reduced 15.91%	10,290 $127,000
Q4 2021 Jan 31, 2022	BUY	$17.78 - $33.08 $26,545 - $49,388	1,493 Added 13.9%	12,237 $279,000
Q3 2021 Oct 29, 2021	BUY	$10.93 - $23.55 $117,431 - $253,021	10,744 New	10,744 $237,000
Q2 2021 Aug 11, 2021	SELL	$10.0 - $14.52 $135,780 - $197,152	-13,578 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$12.3 - $18.73 $167,009 - $254,315	13,578 New	13,578 $176,000

208

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.